GlassScriptPhysician profile
Jessica Torres
NPI 1104499292
$6,138.68
in general payments reported to CMS, 2019-2025
26 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $846 · 2023: $1,949 · 2024: $1,771 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,924.96 |
| Education | $367.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,336.02 | 2022-2025 | |
| Abbvie INC. | $910.17 | 2022-2025 | |
| Janssen Biotech, INC. | $680.01 | 2022-2025 | Tremfya |
| Genzyme Corporation | $444.05 | 2023-2025 | |
| Pfizer INC. | $395.03 | 2022-2025 | |
| Amgen INC. | $351.95 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $270.56 | 2022-2025 | Dupixent, Libtayo |
| Gilead Sciences, INC. | $243.21 | 2024-2025 | Livdelzi |
| Dermavant Sciences, INC. | $242.29 | 2023-2024 | Vtama |
| Lilly USA, LLC | $236.26 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $165.89 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $163.84 | 2023-2025 | Adbry |
| Journey Medical Corporation | $153.91 | 2022 | |
| Sun Pharmaceutical Industries INC. | $108.52 | 2023-2025 | Absorica Ld, Winlevi |
| Biofrontera INC. | $62.09 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $57.66 | 2022-2025 | Nemluvio, Aklief |
| Ucb, INC. | $50.32 | 2023-2024 | Bimzelx |
| Organon LLC | $48.84 | 2025 | Vtama |
| Lnhc, INC | $47.74 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $38.11 | 2024-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.06 | 2023-2024 | Arazlo, Jublia |
| Smith+Nephew, INC. | $25.08 | 2023 | Collagenase Santyl |
| Almirall LLC | $24.12 | 2025 | Klisyri |
| Incyte Corporation | $16.65 | 2023 | Opzelura |
| Cala Health, INC. | $15.42 | 2025 | Cala Kiq |
| Helsinn Therapeutics (U.S.), INC. | $14.88 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.